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Abstract
Enduring interest in the Apolipoprotein E (ApoE) polymorphism is ensured by its evolutionary-driven uniqueness in humans
and its prominent role in geriatrics and gerontology. We use large samples of longitudinally followed populations from the
Framingham Heart Study (FHS) original and offspring cohorts and the Long Life Family Study (LLFS) to investigate gender-
specific effects of the ApoE4 allele on human survival in a wide range of ages from midlife to extreme old ages, and the
sensitivity of these effects to cardiovascular disease (CVD), cancer, and neurodegenerative disorders (ND). The analyses show
that women’s lifespan is more sensitive to the e4 allele than men’s in all these populations. A highly significant adverse
effect of the e4 allele is limited to women with moderate lifespan of about 70 to 95 years in two FHS cohorts and the LLFS
with relative risk of death RR = 1.48 (p = 3.661026) in the FHS cohorts. Major human diseases including CVD, ND, and cancer,
whose risks can be sensitive to the e4 allele, do not mediate the association of this allele with lifespan in large FHS samples.
Non-skin cancer non-additively increases mortality of the FHS women with moderate lifespans increasing the risks of death
of the e4 carriers with cancer two-fold compared to the non-e4 carriers, i.e., RR = 2.07 (p = 5.061027). The results suggest a
pivotal role of non-sex-specific cancer as a nonlinear modulator of survival in this sample that increases the risk of death of
the ApoE4 carriers by 150% (p = 5.361028) compared to the non-carriers. This risk explains the 4.2 year shorter life
expectancy of the e4 carriers compared to the non-carriers in this sample. The analyses suggest the existence of age- and
gender-sensitive systemic mechanisms linking the e4 allele to lifespan which can non-additively interfere with cancer-
related mechanisms.
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Introduction
The Apolipoprotein E (ApoE) common polymorphism (e2, e3,
and e4) is one of the most studied genetic variants in humans. The
interest in this polymorphism is two-fold. First, the functional
diversity of the ApoE polymorphism appears to be a unique
signature of humans with no coding variation in this gene even in
human’s closest ancestries in which the monomorphic ApoE
sequence resembled human’s e4 allele [1,2]. Understanding the
functional diversity of the ApoE gene, thus, can help in gaining
insights on human evolution. Second, the ApoE polymorphism is
of fundamental interest for geriatrics and gerontology because of
its profound role in human diseases in late (post-reproductive) life
and lifespan.
Most consistent associations were reported for the detrimental
effect of the e4 allele on Alzheimer disease [3–5]. Studies also
mostly documented a detrimental role of the e4 allele in
cardiovascular health [6,7] although a protective role of this allele
was also reported [6,8]. The e4 allele was associated with human
lifespan and longevity in a number of studies [9–19]; some studies
reported, however, no significant effect [20–22] (see also http://
genomics.senescence.info/longevity). Studies of the role of the e4
allele in human longevity were mostly limited to comparing
frequencies of genotypes in long-living individuals and younger
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controls [23], a strategy which has limitations [24]. Studies
examining survival of older individuals carrying the e4 allele are
rare (notably, [17,18]). Sexual dimorphism of the ApoE gene in
human survival has not been widely studied so far (see [17] and
references therein).
Since the e4 allele may be involved in regulation of such
common diseases in the elderly as dementia and cardiovascular
diseases (CVD), it is often assumed that the detrimental effect of
the e4 allele on human longevity is mediated by these diseases
(e.g., [11,14,25]). Studies of the systemic effect of the e4 allele and
major human diseases on lifespan in the same samples are rare
[16,17] primarily because they require large samples of genotyped
individuals followed for a long period of time to have sufficient
number of events.
Despite the detrimental role of the e4 allele in human health
and longevity, this allele continues to be widespread in human
population [26]. The persistence of this allele has been proposed to
be a result of balancing selection implying that the e4 allele should
be also evolutionarily advantageous with a beneficial role in early
life [27–30].
In this work we examine three inter-related problems which,
taken together, address the systemic role of the e4 allele in human
lifespan. First, we investigate gender-specific effects of the ApoE4
allele on survival in a wide range of ages starting from midlife to
extreme old ages. Second, we examine whether major human
diseases such as CVD, cancer, and neurodegenerative disorders
(ND) can explain (i.e., mediate) the effect of the e4 allele on
survival. Third, we investigate whether these diseases can
modulate the e4-specific survival non-additively. This wide range
of systemic analyses is possible given the large sample with directly
genotyped ApoE polymorphism available for the analyses and
selected from the Framingham Heart Study (N=5182) and the
Long Life Family Study (N=4659) followed longitudinally for up
to 60 years with a total of 2557 deaths.
Results
The proportions of the ApoE4 allele carriers (see Methods) and
the allele-specific proportions of deaths, CVD, cancer, and ND are
given in Table 1. Table 1 shows that the proportion of the e4 allele
carriers is about the same regardless of gender in FHS and FHSO
cohorts at the time of biospecimens collection, i.e., 20.6% FHS
men, 22.3% FHSO men, 22.8% FHS women, and 22.7% FHSO
women carry the e4 allele. The FHSO sample of genotyped
survivors (mean age of about 50 years) was, however, about 20
years younger than that in the FHS at the time of biospecimens
collection (Table 1) indicating no strong e4-specific survival
selection by that time in the FHS and FHSO survivors. The
proportion of the e4 allele carriers in the LLFS was the largest in
spouses; it was (significantly [31]) smaller in children of the long-
living individuals compared to spouses; it declined in the selected
population of long-living individuals compared to younger
populations.
Empirical Age Patterns of Survival of the FHS and LLFS
Men and Women
Our empirical analysis showed no consistent detrimental effect
of the e4 allele across ages on the survival of men either in the FHS
or FHSO cohorts (Figures 1A and 1C). Contrary to men, the e4
female carriers have shorter lives than the non-carriers (Figures 1B
and 1D). An important result is that the role of the e4 allele in
survival can change with age. Specifically, there is no e4-specific
difference in survival of either the FHS men or women at ages 95
years and older (Figures 1A and 1B). The e4 allele does not affect
survival at ages 70 years and younger (Figure 1D) either.
Analysis of survival age patterns of the LLFS male and female
offspring/spouses directly supports these observations. Specifically,
the LLFS female offspring and spouses carrying the e4 allele show
worse survival than those who do not carry this allele (Figure 2D).
Survival of the LLFS male offspring and spouses is not sensitive to
this allele (Figure 2C).
To better understand survival age patterns of the LLFS
participants from the parental generation (Figures 2A–B), one
should keep in mind that this is a population selected for its
exceptional chances to live a long life based on family history and
their own survival to old ages (see Methods). Accordingly, this
population resembles the subpopulation of individuals who survive
to the very old ages in the FHS original cohort rather than the
entire sample of a normal population in this cohort. Then, an
important result is that the LLFS women selected for their chances
of exceptional longevity (Figure 2B) and the long-living women in
the FHS original cohort (represented in Figure 1B by a tail of the
survival age pattern) have the same lifespan regardless of whether
they carry the e4 allele. When analyzing survival age patterns one
should also consider the possibility of survival selection in aging
cohorts; if this selection is sensitive to a specific genetic variant
then we may have biased empirical age patterns for carriers of
genotypes from this variant particularly at advanced ages. Then,
although the lifespans of the long-living LLFS men may be
sensitive to the e4 allele (Figure 2A), further analyses are necessary
(see next subsection) to determine whether this effect is real.
Thus, Figures 1B and 2B document an important result that
survival of long-living women participating in the FHS (see upper
tail in Figure 1B) and LLFS is insensitive to the e4 allele.
Figures 1D and 2D show another remarkable result that the effect
of the e4 allele on survival in the FHSO and LLFS offspring/
spouses is pronounced: (i) starting at the same age, 70 years and (ii)
in women only.
Risks of Death of the FHS and LLFS Men and Women
We evaluated the sensitivity of the survival of the long-living
LLFS men to the e4 allele seen in Figure 2A. Evaluation of the
relative risk (RR) of death for the e4 allele carriers using a model
Author Summary
Discovering genetic origins of healthspan and lifespan
could lead to breakthroughs in increasing the years of
healthy and long life. In this paper we characterize the
association of the e4 allele of the well-studied ApoE gene
with lifespan in two generations of participants of large
longitudinal studies, the Framingham Heart Study and the
Long Life Family Study, and investigate the role of major
human diseases such as cardiovascular disease, cancer,
and neurodegenerative disorders in this association. This
wide range of systemic analyses is possible given the large
sample with directly genotyped ApoE polymorphism
available from these studies (N = 9841, with 2557 deaths).
The analyses show that women’s lifespan is more sensitive
to the e4 allele than men’s in these populations. However,
the strongly adverse effect of the e4 allele is not observed
for all women, but only for those 70 to 95 years old.
Cardiovascular disease, cancer, and neurodegenerative
disorders do not mediate the association of the e4 allele
with lifespan. However, cancer, but not cardiovascular and
neurodegenerative diseases, non-additively enhances this
effect resulting in 4.2 years of difference in mean lifespan
for the e4 allele carriers compared to the non-carriers.
ApoE, Human Diseases, and Lifespan
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without adjustment for birth cohorts supported the presence of the
effect (RR=1.52, p = 6.961023) in this sample (Table 2). How-
ever, adjustment for birth cohorts entirely explained this
association (RR=1.17, p = 0.319; Table 2), suggesting that this
sensitivity was likely due to differential survival of the e4 carriers
and non-carriers in different birth cohorts in the LLFS.
The relative risks obtained from the data in Figures 1 and 2
revealed the presence of a significant detrimental effect of the e4
allele on survival in women in the FHS (RR=1.25, p = 0.027),
FHSO (RR=1.59, p= 2.461024), and LLFS offspring/spouse
(LLFS_O+S; RR=2.23, p = 5.261023) samples (Table 2, all). No
significant effect was seen in men in either sample or in long-living
women in the LLFS (Table 2, all). Pooled data from the FHS and
FHSO slightly improved the significance of the estimates for
women, RR=1.36, p = 1.361024 (Table 2, FHS+FHSO, all).
However, given the empirical evidence on the substantial role of
age-related heterogeneity (Figures 1 and 2), analyses of the relative
risks using the Cox proportional hazards regression model, which
disregards such heterogeneity, likely underestimate the effects. A
more appropriate way to address the impact of age-related
heterogeneity is to consider more homogeneous groups of
individuals for whom the variation of the hazards is proportional
over age. Empirical evidence from independent FHS and LLFS
cohorts (Figures 1 and 2) suggests selecting more homogeneous
groups of individuals who died or were censored at ages: (i)
younger than 95 years in the FHS (note that there were virtually
no genotyped individuals with lifespans less than 70 years in this
sample), (ii) 70 years and older in the FHSO and LLFS_O+S
(note, virtually all genotyped participants in these samples had
lifespans less than 95 years), and (iii) 70 to 95 years in the pooled
sample of the FHS and FHSO.
Table 2 shows that individuals from these more homogeneous
groups in each sample are at substantially larger risk of death
compared to the entire sample. For example, we observe 9%
increment (from RR=1.36 to RR=1.48) in the risk of death in
the more homogeneous 70–95 year group of the FHS and FHSO
women. Correspondingly, the significance of the estimate also
sharply increases from p= 1.361024 to 3.661026.
Importantly, the analyses also confirm the lack of a significant
effect of the e4 allele on survival in the groups of individuals who
did not belong to the selected more homogeneous groups (Table 2).
Specifically, no significant effects were observed in: (a) the groups
Table 1. Proportions of the ApoE4 allele carriers, mean age at the time of biospecimens collection, and the allele-specific
proportions of deaths, CVD, cancer, and ND for the genotyped participants of the FHS, FHSO, and LLFS.
Study e4 N (%*) Age (SD) years*** Death CVD Cancer ND
N % N % N % N %
Men
FHS no 362** 73.1 (5.4) 322 89.0 260 71.8 151 41.7 77 21.3
yes 94 (20.6) 74.5 (5.6) 85 90.4 66 70.2 33 35.1 26 28.3
FHSO no 1456 51.8 (10.2) 346 23.8 451 31.0 377 25.9 19 1.3
yes 418 (22.3) 52.5 (10.1) 111 26.6 148 35.4 97 23.2 17 4.2
LLFS_P no 567 90.0 (5.7) 276 48.7
yes 95 (14.4) 88.3 (5.2) 46 48.4
LLFS_O no 778 60.6 (8.4) 23 3.0
yes 203 (20.7) 60.3 (7.8) 3 1.5
LLFS_S no 333 65.1 (10.4) 23 6.9
yes 116 (25.8) 65.3 (9.7) 9 7.8
Women
FHS no 619** 74.2 (5.7) 494 79.8 392 63.3 194 31.3 146 23.9
yes 183 (22.8) 73.8 (5.7) 155 84.7 94 51.4 48 26.2 66 36.9
FHSO no 1584 51.5 (10.1) 203 12.8 280 17.7 317 20.0 15 1.0
yes 466 (22.7) 51.1 (9.3) 81 17.4 99 21.2 86 15.5 12 2.6
LLFS_P no 636 91.0 (6.9) 287 45.1
yes 86 (11.9) 89.3 (5.7) 30 34.9
LLFS_O no 1069 60.4 (8.3) 23 2.2
yes 271 (20.2) 61.0 (7.7) 10 3.7
LLFS_S no 379 65.0 (13.6) 19 5.0
yes 126 (25.0) 64.4 (13.3) 11 8.7
FHS = the Framingham Heart Study (FHS) original cohort; FHSO= the FHS offspring cohort.
LLFS_P = long-living parental generation of the Long Life Family Study (LLFS) participants; LLFS_O=offspring of the LLFS long-living participants; LLFS_S = spouses of
the LLFS long-living participants and their offspring.
CVD= cardiovascular diseases including diseases of heart and stroke; Cancer = all sites but skin; ND=dementia and Alzheimer disease combined; SD= standard
deviation.
*proportion of the ApoE4 allele carriers is in percentages;
**maximal sample size; the number of individuals with non-missing information on ND is about 1% less in the FHS and about 3% less in the FHSO.
***age at biospecimens collection at the 19th FHS, 4th FHSO and baseline LLFS examinations.
The ApoE4-allele-specific proportions of CVD, cancer, and ND are not given for the LLFS because this information was not used in this paper.
doi:10.1371/journal.pgen.1004141.t001
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of individuals with lifespans less than 70 years in the FHSO and
LLFS_O+S, (b) individuals with exceptional survival including the
entire sample of the LLFS long-living men and women (LLFS_P),
and (c) individuals who were aged 95 years and older in the FHS.
The lack of significant effects cannot be explained by the sample
size differences (Table 2).
Do Cancer, CVD, and ND Explain the Association of the
e4 Allele with Lifespan?
To address this question, we focused on the more homogeneous
groups of participants of the FHS original and FHSO cohorts
defined in the previous subsection (the LLFS sample is underpow-
ered for such analyses) in order to diminish bias attributable to
disproportionality of hazards when using the Cox regression model.
Given slightly smaller samples of the FHS participants with known
ND status (Table 1), these analyses were limited to individuals with
missing information on ND excluded (sample sizes are provided in
the respective tables along with the effect estimates).
Additive adjustments of the Cox regression models estimating
the risk of death for carriers and non-carriers of the e4 allele by (i)
CVD, (ii) CVD and cancer, and (iii) CVD, cancer, and ND,
reveal that CVD and cancer do not explain the observed
associations. Contrarily, CVD and cancer tend to improve the
estimates in each sample with a more pronounced role for cancer
(Figure 3). ND plays at most minor mediating role in the
associations of the e4 allele with survival of either men (Figure 3A)
or women (Figure 3B). Thus, none of these diseases explain the
association of the e4 allele with risks of death (see Supplementary
Information, Table S1).
Do Cancer, CVD, and ND Nonlinearly Modulate the Effect
of the e4 Allele on Lifespan?
Given no qualitative difference in the additive role of CVD,
cancer, and ND in the e4-specific risks of death across the FHS
samples, we evaluated the risks in the largest more homogeneous
pooled sample of the FHS and FHSO participants in disease-
stratified analyses (see Methods). Figure 4 and Table 3 show that
the risks of death for women are the same regardless of CVD or
ND status, i.e., neither CVD nor ND increase mortality of the e4
female carriers nonlinearly even after adjustment for alternative
Figure 1. Empirical age patterns of survival of the ApoE4 carriers and non-carriers in the FHS. Patterns are shown for (A and C) men and
(B and D) women genotyped in (A and B) FHS and (C and D) FHSO cohorts who carry (E4) and do not carry (NoE4) the ApoE4 allele. The numbers in
the insets show the total number of genotyped individuals and the number of deaths among them.
doi:10.1371/journal.pgen.1004141.g001
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diseases. These diseases do not non-additively modulate men’s
survival either.
A striking result was that non-skin cancer significantly (p = 0.029
for multiplicative interaction of cancer with ApoE) differentiated
the e4-specific risks of death for women from the more
homogeneous group (with moderate lifespans of 70 to 95 years)
increasing them by 52% from RR=1.36 (p= 3.861023) for
women who did not have cancer to RR=2.07 (p= 5.061027) for
women who had cancer (Figure 4B and Table 3). The high risk of
death for women with moderate lifespan who had cancer
explained the 3.2-year shorter life expectancy for the e4-allele
carriers compared to the non-carriers (Table 4). The same trend
on the e4-specific excess in the risks of death was seen for male
cancer patients compared to non-patients (Figure 4A). Cancer
increases risks for the e4 allele carriers compared to the non-
carriers making them marginally significant, RR=1.31 (p= 0.080)
(Table 3).
The available sample size allowed us to gain some insights on
potential differences between cancer sites (other than skin) in these
associations. In these analyses we excluded major sex-specific sites,
i.e., prostate in men and breast in women. Figure 5 and Table 3
show that relative risks of death for men without non-sex-specific
cancers (RR=1.11) increases compared to men without cancers
(RR=1.03) but it declines for men having non-sex-specific cancers
(RR=1.17) compared to men having cancers (RR=1.31). This
pattern suggests that the potential modulating effect of cancer in
men is likely not sensitive to cancer site. Contrary to men, Figure 5
and Table 3 show that modulating role of cancer in women is
entirely attributed to non-sex-specific cancers. The relative risk of
death for women with moderate lifespan who had non-sex-specific
cancers became much more pronounced (RR=2.51,
p = 5.361028). This high risk explained the 4.2-year difference
in life expectancy for the e4-allele carriers and non-carriers in this
group (Table 4).
Figure 2. Empirical age patterns of survival of the ApoE4 carriers and non-carriers in the LLFS. Patterns are shown for (A and C) men, (B
and D) women; and for (A and B) long-living individuals (LLFS_P) and (C and D) offspring of long-living individuals and spouses (LLFS_O+S) who carry
(E4) and do not carry (NoE4) the ApoE4 allele. By design, the LLFS included long-living individuals who were aged 80+ years at entry. Offspring of
long-living individuals and spouses were pooled together because of the small number of deaths among them (Table 1). The numbers in the insets
show the total number of genotyped individuals and the number of deaths among them.
doi:10.1371/journal.pgen.1004141.g002
ApoE, Human Diseases, and Lifespan
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Discussion
The e4 Allele and Human Lifespan
Analysis of genotyped offspring in the FHS revealed that the e4
allele is irrelevant to survival in mid to early-old life, up to about
70 years (Table 2). This result appeared to be corroborated in an
independent population of the LLFS offspring and spouses
(Table 2). The e4 allele changed its role from neutral in mid to
early-old life to detrimental at older ages. This change was found
in independent samples of the FHS Offspring cohort (Figure 1D)
and the LLFS offspring and spouses (Figure 2D). Moreover, this
change occurred concordantly in the FHSO and LLFS: (i) at about
the same age of 70 years and (ii) in women only. The detrimental
effect of the e4 allele at old ages (until 95 years of age) was also
found in a sample of the FHS women (Figure 1B; note that
virtually no individuals with lifespan less than 70 years were
genotyped in this cohort).
At extreme ages (95 years and older) we concordantly observed
a neutral role of the e4 allele in each gender in the FHS (Figures 1A
and 1B). Analysis of the long-living individuals in the LLFS
corroborated these findings (see the ‘‘Empirical Age Patterns
of Survival of the FHS and LLFS Men and Women’’ and
‘‘Risks of Death of the FHS and LLFS Men and Women’’
subsections).
Overall, these analyses demonstrated a strong detrimental effect
of the e4 allele on survival which was mostly attributed to women
with moderate lifespans of 70 to 95 years in the FHS, FHSO, and
LLFS. For example, the e4 allele increased the risks of death of the
FHS and FHSO women by about 48% (RR=1.48) with very high
confidence, p= 3.661026 (Table 2).
Although our study provided robust evidence of a women-
specific detrimental effect of the e4 allele on lifespan in three
different samples of mostly North-American population (i.e., FHS,
FHSO, and LLFS, see Methods), there is also robust evidence of a
detrimental effect of this allele in Swedish men but not women
[17]. Further, although our results on the neutral role of the e4
allele at extreme ages (95 years and older) are in agreement with
some meta-analyses [e.g., 32], there is also evidence of a significant
detrimental effect of the e4 allele at those ages in the Danish
population [18]. The results by Rosvall et al. [17], Jacobsen et al.
[18], and ours explicitly show that the effect of the e4 allele on
lifespan may not be the same in different populations. These
robust evidences from different populations illustrate that the
concept of replication of the same effect of the same allele on the
same complex phenotype characteristic for post-reproductive
period has inherent limitations [33–36].
The e4 Allele, Human Lifespan, and Additive Effects of
Major Diseases
The e4 allele is a major susceptibility allele for Alzheimer
disease (which is a subtype of the ND in this study) particularly in
Caucasians [4] (but may be not in Hispanics [37]). Despite that,
our well-powered analyses show that ND explains at most a tiny
part in the association of the e4 allele with survival (Figure 3). The
results of our analyses do not support the hypothesis that the lack
of a mediating effect of ND can be due to potential ND
misclassification. This is evidenced in Figure 3 by: (i) the tiny
reduction of the effect size attributed to ND (Figure 3) despite the
large prevalence of ND (particularly in the FHS as the older
cohort, Table 1), and (ii) the role of cancer as a nonlinear
modulator of the effect of the e4 allele on survival (Figure 4).
Additive contributions of the e4 allele and dementia to survival
was also observed in other studies [16] although the attenuation of
the effect size by dementia varied [17].
Despite the associations of the e4 allele with CVD [6,7] and
with CVD-free life [19,38], our analyses show that CVD does not
explain the effect of the e4 allele on women’s survival (Figure 3).
Recent analyses support these results by showing independent
associations of the e4 allele and various characteristics of
cardiovascular health and CVD with survival [16,17,39].
Several studies reported on a role of the ApoE gene in cancer
[40–43]. It has been also shown that the e4 allele can increase
cancer-free lifespan in the FHS and FHSO men [19,38]. The
Table 2. Relative risks of death for the ApoE4 allele carriers
compared to the non-carriers in the selected age groups of
the genotyped participants of the FHS original, FHSO, and
LLFS cohorts.
Cohort Age group Ntotal Ndied RR p 95% CI
Men
FHS All 456 407 1.16 0.239 0.91–1.48
FHSO All 1874 457 1.08 0.492 0.87–1.33
FHS+FHSO All 2330 864 1.12 0.178 0.95–1.31
LLFS_P* All 661 322 1.52 6.961023 1.12–2.06
LLFS_P All 661 322 1.17 0.319 0.86–1.60
LLFS_O+S All 1430 58 0.81 0.537 0.41–1.59
FHS $95 29 22 2.00 0.214 0.67–5.96
FHS ,95 427 385 1.18 0.195 0.92–1.53
FHSO $70 892 277 1.13 0.365 0.87–1.48
FHSO ,70 982 180 0.97 0.831 0.71–1.32
FHS+FHSO $70–,95 1319 662 1.17 0.096 0.97–1.40
LLFS_O+S $70 484 44 0.64 0.294 0.28–1.47
LLFS_O+S ,70 946 14 1.20 0.328 0.37–3.86
Women
FHS All 802 649 1.25 2.761022 1.03–1.52
FHSO All 2050 284 1.59 2.461024 1.24–2.05
FHS+FHSO All 2852 933 1.36 1.361024 1.16–1.60
LLFS_P* All 722 317 0.98 0.924 0.66–1.45
LLFS_P All 722 317 0.78 0.279 0.50–1.22
LLFS_O+S All 1845 63 2.23 5.261023 1.27–3.90
FHS $95 126 90 0.94 0.794 0.57–1.55
FHS ,95 676 559 1.37 1.761023 1.12–1.66
FHSO $70 987 188 1.80 1.361024 1.33–2.43
FHSO ,70 1063 96 1.10 0.638 0.74–1.65
FHS+FHSO $70–,95 1663 747 1.48 3.661026 1.26–1.75
LLFS_O+S $70 596 50 3.04 7.861024 1.59–5.81
LLFS_O+S ,70 1249 13 0.40 0.394 0.05–3.28
RR = relative risk; CI = Confidence interval; Ntotal and Ndied denote the total
number of genotyped individuals and the number of deaths among them,
respectively.
All models were adjusted for birth cohorts measured as a continuous variable
except the model for long-living men and women from the LLFS parental
generation (LLFS_P) denoted by asterisk (*). Models for pooled samples in the
FHS (i.e., the FHS original and FHSO cohorts; denoted as FHS+FHSO) and LLFS
(i.e., the LLFS offspring and spouses; denoted as LLFS_O+S) were adjusted for
potential cohort differences. Models for the LLFS were also adjusted for
potential field center differences.
‘‘All’’ in column ‘‘Age group’’ denotes the sample of all ages; other notations in
this column indicate the range of ages at death or the end of follow up in each
sample. For example, ‘‘$70’’ implies a group of individuals who died at 70+
years or was aged 70+ years at the end of follow up.
doi:10.1371/journal.pgen.1004141.t002
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analyses in this study show no mediating role of cancer in the
association of the e4 allele with women’s survival; the additive
contribution of cancer, however, can modulate the effect of the e4
allele, increasing the strength of this association (Figure 3).
CVD and cancer are the most common causes of death in
humans and ND is fast growing cause of death in the elderly. CVD
and ND are the diseases which have been most consistently
associated with ApoE4. Despite that, these diseases do not explain
Figure 3. Relative risks of death and p-values for the ApoE4 allele carriers compared to the non-carriers. The risks were evaluated in
more homogeneous groups of (A) men and (B) women who died or were right censored at ages: (i) younger than 95 years in the FHS, (ii) 70 years and
older in the FHSO, and (iii) 70 to 95 years in the pooled sample of the FHS and FHSO cohorts. The basic model denotes adjustment for birth cohorts
(all models) and an indicator of the FHS or FHSO in the pooled sample (FHS+FHSO). Adjustments by diseases are additional to the basic adjustment.
Thin bars show 95% confidence intervals. Exact numeric values for the estimates and sample sizes are given in Supplementary Table S1. Right y-axes
show (A) minus log-base-10-transformed p-values and (B) log-base-10-transformed p-values. (A) The horizontal line and (B) upper x-axis show the
conventional level of significance, i.e., |log10(0.05)| = 1.3.
doi:10.1371/journal.pgen.1004141.g003
Figure 4. Disease-stratified relative risks of death and p-values for the ApoE4 allele carriers compared to the non-carriers. The risks
were evaluated in a more homogeneous group of (A) men and (B) women who died or were right censored at ages 70 to 95 years in the pooled
sample of the FHS and FHSO cohorts. The models were adjusted for birth cohorts, an indicator of the FHS or FHSO, and additive contributions of CVD,
ND, and cancer, as applicable, e.g., the model for samples stratified by CVD was adjusted by cancer and ND. Multiplicative interaction between ApoE
and cancer for women is significant (p = 0.029). Thin bars show 95% confidence intervals. Exact numeric values for the estimates and sample size are
given in Table 3. Right y-axes show (A) minus log-base-10-transformed p-values and (B) log-base-10-transformed p-values. (A) The horizontal line and
(B) upper x-axis show the conventional level of significance, i.e., |log10(0.05)| = 1.3.
doi:10.1371/journal.pgen.1004141.g004
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the detrimental role of the e4 allele in lifespan. This finding implies
the existence of a mechanism linking the e4 allele with lifespan
which is largely independent of the mechanisms affecting
susceptibility to CVD, cancer, and ND. Given also that the e4
allele may not be associated with frailty [14,44], it is likely that this
allele can be directly involved in regulation of human aging
through intrinsic biological mechanisms. One potential mecha-
nism could be associated with inflammation which may be
involved in aging through two main pathways associated with
‘‘immunosenescence and synergies with chronic diseases that have
inflammatory components’’ [29]. Given no mediating role of
CVD, cancer, and ND observed in our study and that these
diseases (particularly CVD and ND) can have e4-specific
inflammatory etiology [8,45], it might well be the case that the
e4 allele affects survival through immunosenescence whereas it
affects the risks of diseases through disease-specific inflammatory
component.
The e4 Allele, Human Lifespan, and Non-Additive Effects
of Major Diseases
Neither CVD nor ND non-additively (i.e., nonlinearly) modu-
lates the detrimental effect of the e4 allele on women’s survival,
i.e., the relative risks of death for the e4 allele carriers are the same
regardless of women’s CVD and ND statuses (Figure 4B). This
result is in line with findings by Little et al. [16]. However, the e4
allele was shown to be mostly associated with dementia-caused
deaths by Newman et al. [39].
We found that cancer showed a significant nonlinear modulat-
ing effect in the association of the e4 allele with women’s survival
(Figure 4B). The e4-positive female cancer patients have about a
two-fold increased risk of death at ages between 70 and 95 years
compared to the non-e4 allele carriers (RR=2.07) which is highly
significant, p = 5.061027 (Table 3). Such a strong effect results in a
3.2-year shorter life expectancy of the e4 carriers compared to the
non-carriers in this sample (Table 4). Further analyses show that
this effect is attributed to non-sex-specific cancer sites, it
substantially increases, i.e., RR=2.51, p = 5.361028 (Table 3),
and it explains the large 4.2 year differential in the life expectancy
(Table 4). Women without cancer carrying the e4 allele are still at
significant risk of death. The same non-additive role of cancer was
found in the effect of the e4 allele on men’s survival, i.e., this allele
negatively affected cancer survivorship (Figure 4A). The dimin-
ished role of cancer as a nonlinear modulator of the effect of the e4
allele on survival in men compared to women can be attributed to
a protective role of this allele in susceptibility to risk of cancer in
men but not in women [19,38], i.e., protection against risks of
cancer may well explain modest risks of cancer survivorship of
male e4 carriers.
Table 3. Disease-stratified relative risks of death for the
ApoE4 carriers compared to the non-carriers in the more
homogeneous group of the FHS and FHSO participants with
lifespans of 70 to 95 years.
Disease
Disease
status Ntotal Ndied RR p 95% CI
Men*
CVD No 614 208 1.18 0.262 0.88–1.59
Yes 675 442 1.14 0.313 0.89–1.45
Cancer No 810 355 1.03 0.810 0.80–1.33
Yes 479 295 1.31 0.080 0.97–1.78
Non-prostate No 981 431 1.11 0.390 0.88–1.40
Yes 308 219 1.17 0.419 0.80–1.70
ND No 1159 527 1.10 0.376 0.89–1.36
Yes 130 123 1.22 0.431 0.75–1.98
Women*
CVD No 955 285 1.64 1.461024 1.27–2.11
Yes 680 447 1.51 2.861024 1.21–1.88
Cancer No 1203 475 1.36 3.861023 1.11–1.68
Yes 432 257 2.07 5.061027 1.56–2.75
Non-breast No 1360 552 1.36 1.761023 1.12–1.66
Yes 275 180 2.51 5.361028 1.80–3.49
ND No 1435 543 1.63 1.861026 1.33–1.99
Yes 200 189 1.49 1.461022 1.08–2.04
*Individuals with missing neurodegenerative disorders (ND) status were
excluded in all models.
CVD= cardiovascular diseases; Cancer includes all sites but skin; Non-prostate
indicates non-skin cancers apart from prostate neoplasm in men; Non-breast
indicates non-skin cancers apart from breast neoplasm in women;
RR = relative risk; CI = Confidence interval; Ntotal and Ndied denote the total
number of genotyped individuals and the number of deaths among them,
respectively.
All models were adjusted for birth cohorts, an indicator of the FHS or FHSO, and
additive contribution of CVD, ND, and cancer, as applicable, e.g., the model for
samples stratified by CVD was adjusted by cancer and ND.
doi:10.1371/journal.pgen.1004141.t003
Table 4. Kaplan-Meier estimates of life expectancy of the FHS and FHSO women from the more homogeneous group who were
aged between 70 and 95 years at death or the end of follow up in 2008 stratified by cancer and the ApoE4 statuses.
Cancer type Cancer status E4 allele Ntotal Ndied LE, years 95% CI
All sites but skin no no 926 353 88.3 87.8–88.8
yes 277 122 87.1 86.3–88.0
yes no 346 195 86.6 85.9–87.4
yes 86 62 83.4 82.0–84.7
All sites but skin & breast no no 1052 412 88.2 87.7–88.6
yes 308 140 87.1 86.2–87.9
yes no 220 136 86.2 85.2–87.1
yes 55 44 82.0 80.4–83.5
LE = life expectancy; CI = confidence interval; Ntotal and Ndied denote the total number of genotyped individuals and the number of deaths among them, respectively.
doi:10.1371/journal.pgen.1004141.t004
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The cancer-sensitive non-additive effect of the e4 allele on
human lifespan suggests that mechanisms associated with cancer
survivorship (i.e., with its progression and/or treatment) can
interfere with a mechanism linking the e4 allele to lifespan. Our
findings are particularly in line with inflammatory pathways
[29,43] which may overlap for aging and cancer survivorship as a
result of the compromising of the immune system with age [46]
(see also next subsection). Thus, the non-additive role of cancer in
the effect of the e4 allele on lifespan and the lack of this role for
CVD and ND likely underscores the synergism between cancer
and aging.
The e4 Allele and Survival in Humans
Given the persistence of the e4 allele in humans, it may be
beneficial in early life and, thus, be subject to balancing selection
[27–30]. Indeed, several studies provided support for a beneficial
role of the e4 allele in early life. For example, it was shown that the
proportion of the e4 allele was significantly smaller in spontane-
ously aborted embryos than in adults [47]. The proportion of the
e4 allele was also found to be significantly larger in healthy
liveborn infants compared with stillborn infants and with adults
[48]. These findings suggest that the e4 allele can benefit early
survival. Then, given the detrimental role of this allele for survival
in old ages, we should expect a neutral role at some point in
between. Our finding of a neutral role of the e4 allele in survival in
mid to early-old life of the genotyped FHS and LLFS participants
supports this logic.
Studies also show that ApoE4 may protect against early life
infectious diseases such as, e.g., diarrhea [49] and liver damage
caused by the hepatitis C virus infection [50,51]. A putative
protective mechanism may be associated with an enhanced
function of the immune system in early life [25] with a role of
ApoE as an immunomodulator [52]. At old ages immunosenes-
cence may be a factor favoring neoplasia [53]. Then, if ApoE4
boosts the immune system in early life, this may naturally lead to
prematurely exhausting this system later in life which may affect
cancer survivorship for carriers of this allele (and, thus, implying
antagonistic pleiotropy). This hypothesis is supported by our
findings of a strong non-additive modulating role of cancer in
survival of female e4 allele carriers (Figure 5), by the very high
proportion of deaths (80%) among female e4 carriers with non-
sex-specific cancer by age 95 years (44 deaths among 55 carriers;
Table 4), and by the 150% excess risk of death for such women
compared to the non-e4 carriers (RR=2.51, p= 5.361028;
Table 3). These high death rates can, in part, explain the
diminishing detrimental effect of ApoE4 at very advanced ages
(95+ years) in the FHS.
The lack of an association of ApoE4 with survival at extreme
ages (95+) in the FHS and in an exceptional population of the
LLFS long-living participants suggests that the detrimental effect
of ApoE4 can be counterbalanced in some individuals. Potential
factors can include buffering mechanisms (by other genes [54])
and/or environmental modulations of genetic effects [36]. Given
large samples of long-living individuals in the LLFS, this study
could be highly promising for revealing such mechanisms.
Concluding Remarks
Analyses of the association of the ApoE4 allele with lifespan in
three populations of the FHS, FHSO, and LLFS participants
showed that women’s lifespan was more sensitive to the e4 allele
than men’s. The adverse role of the e4 allele was limited to women
with moderate lifespans of about 70 to 95 years; no survival
disadvantage is seen for women with lifespans less than 70 or more
than 95 years. The highly significant association of the e4 allele
with lifespan was not explained by major diseases including CVD,
ND, and cancer, whose risks can be sensitive to this allele, in large
FHS samples. Non-skin cancer non-additively increased mortality
of the FHS women with moderate lifespans increasing the risks of
death of the e4 carriers two-fold compared to the non-carriers.
High and highly significant risks of death of the e4-allele carriers in
this sample explained their 3.2 year shorter life expectancy. The
results suggest a pivotal role of non-sex-specific cancer as a
nonlinear modulator of survival in this sample of women that
increased the risk of death of the ApoE4 carriers by 150%
(p= 5.361028) compared to the non-carriers and explained the
4.2 year differential in life expectancy in this group. Our results
suggest the existence of age- and gender-sensitive systemic
mechanisms linking the e4 allele to lifespan which can non-
additively interfere with cancer-related mechanisms.
Methods
Data
The Framingham Heart Study (FHS). The original (FHS)
cohort was launched in 1948 in Framingham, Massachusetts. 22
years later a cohort of offspring of participants of the FHS original
cohort was launched (known as the FHS Offspring or FHSO
cohort). The study design has been previously described [55–57].
Briefly, the FHS includes N= 5,209 respondents aged 28–62 years
at baseline who have been biennially followed during nearly
60 years. The FHSO respondents (N=5,124) aged 5–70 years
at baseline were biological descendants (N= 3,514), their
spouses (N=1,576), and adopted offspring (N= 34) of the FHS
Figure 5. Cancer-stratified relative risks of death and log-base-
10-transformed p-values for the ApoE4 allele carriers com-
pared to the non-carriers. The risks were evaluated in more
homogeneous groups of individuals who died or were right censored
at ages 70 to 95 years in the pooled sample of the FHS and FHSO. ‘‘No’’
indicates individuals who did not have non-skin cancers apart from
prostate neoplasm in men or breast neoplasm in women. ‘‘Yes’’
indicates individuals who had non-skin cancers other than prostate
neoplasm in men or breast neoplasm in women. The models were
adjusted for birth cohorts, an indicator of the FHS or FHSO, and additive
contribution of CVD and ND. The multiplicative interaction between
ApoE and non-sex-specific cancer in women was highly significant
(p = 5.261023). Thin bars show 95% confidence intervals. Exact numeric
values for the estimates and sample size are given in Table 3 (non-
prostate and non-breast). The solid horizontal line shows the
conventional level of significance, i.e., log10(0.05) =21.3.
doi:10.1371/journal.pgen.1004141.g005
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participants who have been examined about every four years at
eight visits.
The FHS/FHSO participants have been followed for the onset
of CVD, cancer, and death through regular examinations at the
FHS clinic, surveillance of hospital admissions, and death registries
since baseline examinations in the FHS and FHSO [55,56],
currently through 2008. Dementia-free survivors who attended
examination 14 in the FHS and examination two in the FHSO
were continuously followed for onset of dementia and Alzheimer
disease [58], currently through 2008.
Biospecimens were mostly collected in the late 1980s, and
through 1990s, from surviving participants [59,60]. The procedure
used for the ApoE genotyping was described in Lahoz et al. [59].
The data available for this study include information on the
ApoE2/3/4 polymorphism for the 1,258 FHS and 3,924 FHSO
participants.
The Long Life Family Study (LLFS). The LLFS collected
data in about equal proportions at four field centers (three in the
U.S., i.e., Boston, New York, and Pittsburg, and one in Denmark)
on families showing exceptional familial longevity (virtually all
participants were whites). The study eligibility criteria were
described elsewhere [61–63].
Briefly, in the U.S., the families eligible for the LLFS must have
two living siblings aged 80+ years, two living offspring of one or
more of the siblings, and a living spouse of one of the offspring who
were considered as controls. In addition, the family must
demonstrate exceptional longevity based on a Family Longevity
Selection Score, which is a summary-measure based on the
survival experience of the oldest living generation of siblings
relative to what would be expected based on birth cohort life tables
[61]. Families with members of this generation who were still alive
and larger sibships were given higher priorities. Finally, an eligible
family was enrolled in the LLFS if at least 3 family members (the
proband, at least one sibling of the proband, and one offspring of
the proband or the sibling) indicated their willingness to
participate.
In Denmark, individuals who would be aged 90+ years during the
study recruitment period were first identified in the Danish National
Register of Persons [62]. Then, using information on the place of
birth and the names, parish registers available in regional archives
were searched to locate the parents of the elderly individuals in
order to identify sibships. The identified subjects were contacted to
further assess the family’s eligibility for participation in the LLFS
using criteria parallel to that used in the U.S.
Information from the 4,954 U.S. and Danish LLFS participants
was collected using similar questionnaires and in-home physical
examinations at baseline between 2006 and 2009. Once enrolled,
the LLFS participants were followed longitudinally. During the
follow up for about 6 years (currently through April 2013) self-
reported information on diseases collected at baseline was updated
and information on vital status was collected.
Biospecimens were collected at baseline. Genotyping of the
ApoE polymorphism was conducted using procedures detailed
elsewhere [31]. The data include information on the ApoE2/3/4
polymorphism for the 4,659 LLFS participants including long-
living individuals (N=1,384, probands and siblings), their
offspring (N= 2,321, children, nieces, and nephews), spouses of
long-living individuals (N=177), and spouses of offspring of long-
living individuals (N= 777). Due to small numbers of spouses of
the long-living individuals, they were pooled together with spouses
of offspring (N= 954).
Analysis
We use data on longitudinally followed FHS/FHSO and LLFS
participants to characterize the role of the ApoE4 allele (e2/4, e3/
4, and e4/4) and non-e4 genotypes (e2/2, e2/3, and e3/3) in the
lifespans of men and women separately.
Associations of the e4 allele with risks of death were
characterized by the Kaplan-Meier estimator and the Cox
proportional hazards regression model. The time variable in the
analyses was age at death or age at the end of follow up. The
model adjustments were explicitly stated when applicable.
To examine whether or not major human diseases can shape
the association of the e4 allele with survival, we considered
additive and nonlinear roles of CVD (diseases of hearth and stroke
combined), cancer, and ND (dementia and Alzheimer disease
combined) in this association. We considered all non-skin cancers
unless explicitly stated. CVD and ND were chosen because they
were most consistently associated with the ApoE polymorphism
[3,6,7,64]. Recent studies also showed that the ApoE polymor-
phism can be associated with cancer [e.g., 41]. These analyses
were conducted using rigorously ascertained information on
diseases in the FHS/FHSO only because the LLFS data are
currently underpowered for such analyses.
To address nonlinear effect of diseases on the association of the
e4 allele with survival, we conducted disease-stratified analyses.
Each disease group included individuals who were diagnosed with
the disease (or died from it) prior to death or the end of follow up
in 2008. Otherwise, individuals were included in the complemen-
tary non-disease group [65].
We used the robust sandwich estimator of variances in the Cox
model to account for potential clustering (e.g., familial). Statistical
analyses were conducted using SAS (release 9.3, Cary, NC, USA).
This study used de-identified data from the FHS and LLFS.
The FHS data are available from the NHLBI through dbGaP. No
new data were collected in this work. As such, this study does not
require either ethics committee approval or written consent.
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